To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter

PHASE2UnknownINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

August 31, 2004

Conditions
Angina Pectoris
Interventions
GENETIC

pVGI.1(VEGF2)

Trial Locations (35)

10021

New York Presbyterian Hospital, New York

10032

Columbia Presbyterian, New York

14642

University of Rochester, Rochester

20010

Washington Heart, Washington D.C.

21218

Medstar Research, Towson

27705

Durham VA Medical Center, Durham

30308

Crawford Long Hospital, Atlanta

30309

Fuqua Heart Center of Piedmont Hospital, Atlanta

30342

St. Joseph Hospital of Atlanta, Atlanta

32209

Shands Hospital - Jacksonville, FL, Jacksonville

35211

Cardiology, P.C., Birmingham

37920

Baptist Hospital of East Tennessee, Knoxville

46290

The Care Group, LLC, Indianapolis

49048

Borgess Research Institute, Kalamazoo

52803

Midwest CV Research Foundation, Davenport

53215

Heart Care Milwaukee, WI, Milwaukee

55407

Minneapolis Heart Institute, Minneapolis

55902

Mayo Clinic Hospital/Rochester, Rochester

60148

Midwest Heart Foundation, Lombard

60201

Evanston Northwestern Healthcare, Evanston

60612

Rush University Medical Center, Chicago

62701

Prairie Cardiovascular, Springfield

68504

Nebraska Heart Institute, Lincoln

73120

Oklahoma Cardiovascular Research, Oklahoma City

75226

Baylor University Hospital, Dallas

75701

Cardiovascular Associates of East Texas, Tyler

77030

Texas Heart Institute, Houston

The Methodist Hospital, Houston

80012

Aurora Denver Cardiology Associates, Aurora

85006

Arizona Heart Institute, Phoenix

85054

Mayo Clinic Hospital/Scottsdale, Phoenix

92037

Scripps Green Medical Center, La Jolla

98104

Swedish Medical Center, Seattle

02135-2997

Caritas St. Elizabeth's Medical Center, Boston

05401

Fletcher Allen Healthcare, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Corautus Genetics

INDUSTRY